UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 282

Sortiert nach

Initiating oral fingolimod treatment in patients with multiple sclerosis

Therapeutic advances in neurological disorders, 2013-07, Vol.6 (4), p.269-275

Singer, Barry A.

2013

Link zum Volltext

Verfügbarkeit prüfen

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Therapeutic advances in neurological disorders, 2021, Vol.14, p.1756286421993999-1756286421993999

2021

Link zum Volltext

Verfügbarkeit prüfen

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Therapeutic advances in neurological disorders, 2023-01, Vol.16, p.17562864231194823-17562864231194823

2023

Link zum Volltext

Verfügbarkeit prüfen

Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

Journal of neurology, 2024-06, Vol.271 (6), p.3116-3130

2024

Link zum Volltext

Verfügbarkeit prüfen

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study

Multiple sclerosis, 2022-07, Vol.28 (8), p.1219-1228

2022

Link zum Volltext

Verfügbarkeit prüfen

Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies

Seminars in neurology, 2016-04, Vol.36 (2), p.140

Singer, Barry A

2016

Link zum Volltext

Verfügbarkeit prüfen

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews

Advances in therapy, 2022-07, Vol.39 (7), p.3199-3213

2022

Link zum Volltext

Verfügbarkeit prüfen

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Advances in therapy, 2022-04, Vol.39 (4), p.1810-1831

2022

Link zum Volltext

Verfügbarkeit prüfen

Fingolimod for the treatment of relapsing multiple sclerosis

Expert review of neurotherapeutics, 2013-06, Vol.13 (6), p.589-602

Singer, Barry A

2013

Link zum Volltext

Verfügbarkeit prüfen

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Multiple sclerosis, 2020-11, Vol.26 (13), p.1719-1728

2020

Link zum Volltext

Verfügbarkeit prüfen

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

Journal of neurology, 2020, Vol.267 (1), p.64-75

2020

Link zum Volltext

Verfügbarkeit prüfen

A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping

Patient preference and adherence, 2021-01, Vol.15, p.975-987

2021

Link zum Volltext

Verfügbarkeit prüfen

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Neurology and therapy, 2024-08, Vol.13 (4), p.1273-1285

2024

Link zum Volltext

Verfügbarkeit prüfen

Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors

Neurology and therapy, 2016-12, Vol.5 (2), p.155-167

2016

Link zum Volltext

Verfügbarkeit prüfen

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

The New England journal of medicine, 2017-01, Vol.376 (3), p.221-234

2017

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

The Lancet (British edition), 2012-11, Vol.380 (9856), p.1829-1839

2012

Link zum Volltext

Verfügbarkeit prüfen

Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

Multiple sclerosis, 2003-02, Vol.9 (1), p.59-62

2003

Link zum Volltext

Verfügbarkeit prüfen

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Neurology, 2016-11, Vol.87 (19), p.1985

2016

Link zum Volltext

Verfügbarkeit prüfen

Bouffées congestives et événements indésirables liés aux bouffées congestives avec le diroximel fumarate (DRF) chez des patients présentant une sclérose en plaques récurrente-rémittente : résultats de l’étude de phase 3 EVOLVE-MS-2

Revue neurologique, 2022-04, Vol.178, p.S118-S118

2022

Link zum Volltext

Verfügbarkeit prüfen

Le diroximel fumarate (DRF) chez les patients atteints de sclérose en plaques récurrente-rémittente : résultats intermédiaires de sécurité et d’efficacité de l’étude de phase 3 EVOLVE-MS-1

Revue neurologique, 2021-04, Vol.177, p.S119-S119

2021

Link zum Volltext

Verfügbarkeit prüfen

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

Neurology, 2009-11, Vol.73 (18), p.1493

2009

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 282

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(242)
Mit Volltextzugriff
(243)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Initiating oral fingolimod treatment in patients with multiple sclerosis

Improved gastrointestinal profile with diroximel fumarate is associated with a positive impact on quality of life compared with dimethyl fumarate: results from the randomized, double-blind, phase III EVOLVE-MS-2 study

Safety and efficacy with alemtuzumab over 13 years in relapsing-remitting multiple sclerosis: final results from the open-label TOPAZ study

Early use of high-efficacy therapies in multiple sclerosis in the United States: benefits, barriers, and strategies for encouraging adoption

Durability of no evidence of disease activity-3 (NEDA-3) in patients receiving cladribine tablets: The CLARITY extension study

Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS Studies

Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study

Parenteral Treatment of Multiple Sclerosis: The Advent of Monoclonal Antibodies

Health-Related Quality of Life with Diroximel Fumarate in Patients with Relapsing Forms of Multiple Sclerosis: Findings from Qualitative Research Using Patient Interviews

Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 Study

Diroximel fumarate in patients with relapsing–remitting multiple sclerosis: Final safety and efficacy results from the phase 3 EVOLVE-MS-1 study

Fingolimod for the treatment of relapsing multiple sclerosis

Efficacy of alemtuzumab in relapsing-remitting MS patients who received additional courses after the initial two courses: Pooled analysis of the CARE-MS, extension, and TOPAZ studies

Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies

Clinical and MRI efficacy of sc IFN β-1a tiw in patients with relapsing MS appearing to transition to secondary progressive MS: post hoc analyses of PRISMS and SPECTRIMS

A Study Comparing Patient and Clinician Perspectives of Treatments for Multiple Sclerosis via Group Concept Mapping

Lymphopenia is Not the Primary Therapeutic Mechanism of Diroximel Fumarate in Relapsing–Remitting Multiple Sclerosis: Subgroup Analyses of the EVOLVE-MS-1 Study

Survey of US Patients with Multiple Sclerosis: Comparison of the New Electronic Interferon Beta-1b Autoinjector (BETACONNECT™) With Mechanical Autoinjectors

Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis

Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial

Rapid onset Mitoxantrone-induced cardiotoxicity in secondary progressive multiple sclerosis

Alemtuzumab improves preexisting disability in active relapsing-remitting MS patients

Bouffées congestives et événements indésirables liés aux bouffées congestives avec le diroximel fumarate (DRF) chez des patients présentant une sclérose en plaques récurrente-rémittente : résultats de l’étude de phase 3 EVOLVE-MS-2

Le diroximel fumarate (DRF) chez les patients atteints de sclérose en plaques récurrente-rémittente : résultats intermédiaires de sécurité et d’efficacité de l’étude de phase 3 EVOLVE-MS-1

Effect of neutralizing antibodies on biomarker responses to interferon beta: the INSIGHT study

Suchergebnisse filtern